ATE294163T1 - Integrin-rezeptor-antagonisten - Google Patents

Integrin-rezeptor-antagonisten

Info

Publication number: ATE294163T1
Authority: AT; Austria
Prior art keywords: beta; alpha; receptor antagonists; integrin receptor; compounds
Prior art date: 1997-12-17

Application number

AT98963136T

Other languages

English (en)

Inventor

Ben C Askew

Paul J Coleman

Mark E Duggan

Wasyl Halczenko

George D Hartman

Cecilia Hunt

John H Hutchinson

Robert S Meissner

Michael A Patane

Garry R Smith

Jiabing Wang

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-17

Filing date

1998-12-14

Publication date

2005-05-15

1998-04-06 Priority claimed from GBGB9807382.8A external-priority patent/GB9807382D0/en

1998-05-26 Priority claimed from GBGB9811295.6A external-priority patent/GB9811295D0/en

1998-12-14 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

2005-05-15 Application granted granted Critical

2005-05-15 Publication of ATE294163T1 publication Critical patent/ATE294163T1/de

Links

229940127449 Integrin Receptor Antagonists Drugs 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
230000002401 inhibitory effect Effects 0.000 abstract 2
201000001320 Atherosclerosis Diseases 0.000 abstract 1
208000006386 Bone Resorption Diseases 0.000 abstract 1
206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
206010027476 Metastases Diseases 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
230000033115 angiogenesis Effects 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
230000024279 bone resorption Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
102000006495 integrins Human genes 0.000 abstract 1
108010044426 integrins Proteins 0.000 abstract 1
208000002780 macular degeneration Diseases 0.000 abstract 1
230000009401 metastasis Effects 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
230000004614 tumor growth Effects 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1
230000029663 wound healing Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Oncology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Vending Machines For Individual Products (AREA)
Ultra Sonic Daignosis Equipment (AREA)
Resistance Heating (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AT98963136T 1997-12-17 1998-12-14 Integrin-rezeptor-antagonisten ATE294163T1 (de)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US6989997P	1997-12-17	1997-12-17
GBGB9807382.8A GB9807382D0 (en)	1998-04-06	1998-04-06	Vitronectin receptor antagonists
US8320998P	1998-04-27	1998-04-27
GBGB9811295.6A GB9811295D0 (en)	1998-05-26	1998-05-26	Vitronectin receptor antagonists
US9262298P	1998-07-13	1998-07-13
PCT/US1998/026484 WO1999031061A1 (en)	1997-12-17	1998-12-14	Integrin receptor antagonists

Publications (1)

Publication Number	Publication Date
ATE294163T1 true ATE294163T1 (de)	2005-05-15

Family

ID=27517453

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98963136T ATE294163T1 (de)	1997-12-17	1998-12-14	Integrin-rezeptor-antagonisten

Country Status (25)

Country	Link
EP (1)	EP1040098B1 (de)
JP (1)	JP3585839B2 (de)
KR (1)	KR20010033248A (de)
CN (1)	CN1284944A (de)
AT (1)	ATE294163T1 (de)
AU (1)	AU739811B2 (de)
BG (1)	BG104605A (de)
BR (1)	BR9813769A (de)
CA (1)	CA2315220C (de)
DE (1)	DE69829996T2 (de)
EA (1)	EA002822B1 (de)
EE (1)	EE200000362A (de)
ES (1)	ES2241192T3 (de)
GE (1)	GEP20032921B (de)
HR (1)	HRP20000401A2 (de)
HU (1)	HUP0100397A3 (de)
ID (1)	ID24955A (de)
IL (1)	IL136495A0 (de)
IS (1)	IS5521A (de)
NO (1)	NO20003114L (de)
NZ (1)	NZ504893A (de)
PL (1)	PL341215A1 (de)
SK (1)	SK9192000A3 (de)
TR (1)	TR200002557T2 (de)
WO (1)	WO1999031061A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9805655D0 (en)	1998-03-16	1998-05-13	Celltech Therapeutics Ltd	Chemical compounds
US6521626B1 (en)	1998-03-24	2003-02-18	Celltech R&D Limited	Thiocarboxamide derivatives
KR20010087125A (ko) *	1998-04-16	2001-09-15	데이비드 비. 맥윌리암스	인테그린 수용체에 대한 인테그린의 결합을 억제하는 화합물
GB9814414D0 (en)	1998-07-03	1998-09-02	Celltech Therapeutics Ltd	Chemical compounds
JP2002522540A (ja) *	1998-08-13	2002-07-23	メルクエンドカムパニーインコーポレーテッド	インテグリン受容体拮抗薬
GB9821061D0 (en)	1998-09-28	1998-11-18	Celltech Therapeutics Ltd	Chemical compounds
GB9826174D0 (en)	1998-11-30	1999-01-20	Celltech Therapeutics Ltd	Chemical compounds
US6518283B1 (en)	1999-05-28	2003-02-11	Celltech R&D Limited	Squaric acid derivatives
DK1187592T3 (da) *	1999-06-02	2007-11-05	Merck & Co Inc	Alfa v-integrinreceptorantagonister
US6534513B1 (en)	1999-09-29	2003-03-18	Celltech R&D Limited	Phenylalkanoic acid derivatives
JP2003510360A (ja)	1999-10-04	2003-03-18	メルクエンドカムパニーインコーポレーテッド	インテグリン受容体拮抗薬
ES2299436T3 (es) *	1999-10-06	2008-06-01	ABBOTT GMBH & CO. KG	Composicion que comprende un inhibidor de tnf-alfa y un antagonista de receptor de integrina alfavbeta3.
US6407241B1 (en)	1999-11-08	2002-06-18	Merck & Co., Inc.	Process and intermediates for the preparation of imidazolidinone αv integrin antagonists
GB2356630A (en)	1999-11-10	2001-05-30	Merck & Co Inc	Intermediates used in the preparation of tetrahydronaphthyridine
JP2003514908A (ja)	1999-11-23	2003-04-22	メルクエンドカムパニーインコーポレーテッド	テトラヒドロ−［１，８］−ナフチリジンに向けた方法および中間体
US6455539B2 (en)	1999-12-23	2002-09-24	Celltech R&D Limited	Squaric acid derivates
WO2001053262A1 (en) *	2000-01-24	2001-07-26	Merck & Co., Inc.	Alpha v integrin receptor antagonists
DE60130910T2 (de)	2000-04-17	2008-07-10	Ucb Pharma, S.A.	Enamin-derivate als zell-adhäsionsmoleküle
US6403608B1 (en)	2000-05-30	2002-06-11	Celltech R&D, Ltd.	3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en)	2000-05-30	2003-04-08	Celltech R&D Limited	2,7-naphthyridine derivatives
JP2004502762A (ja)	2000-07-07	2004-01-29	セルテック　アール　アンド　ディ　リミテッド	二環性ヘテロ芳香環を含有するインテグリンアンタゴニストとしてのスクエア酸誘導体
JP2004505110A (ja)	2000-08-02	2004-02-19	セルテック　アール　アンド　ディ　リミテッド	３位置換イソキノリン−１−イル誘導体
AU2001290772A1 (en) *	2000-09-14	2002-03-26	Merck And Co., Inc.	Alpha v integrin receptor antagonists
US6444680B1 (en)	2000-11-30	2002-09-03	Merck & Co., Inc.	Amine salts of an integrin receptor antagonist
US6764842B2 (en)	2001-03-28	2004-07-20	Merck & Co., Inc.	Enantioselective bioreduction for the preparation of integrin receptor antagonist intermediates
ES2366775T3 (es)	2001-04-24	2011-10-25	Merck Patent Gmbh	POLITERAPIA UTILIZANDO AGENTES ANTIANGIOGÉNICOS Y TNF(alfa).
WO2002102374A1 (en) *	2001-06-19	2002-12-27	Merck & Co., Inc.	Amine salt of an integrin receptor antagonist
US20040224986A1 (en)	2002-08-16	2004-11-11	Bart De Corte	Piperidinyl targeting compounds that selectively bind integrins
GB0420424D0 (en) *	2004-09-14	2004-10-20	Ionix Pharmaceuticals Ltd	Therapeutic compounds
AU2007207465B2 (en)	2006-01-18	2012-12-06	Merck Patent Gmbh	Specific therapy using integrin ligands for treating cancer
BRPI0806596A2 (pt)	2007-01-18	2013-07-23	Merck Patent Ges Mit Berchraenkter Haftung	medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer
WO2009114776A2 (en)	2008-03-14	2009-09-17	Visen Medical, Inc.	Integrin targeting agents and methods of using same
EP2445534A2 (de)	2009-05-25	2012-05-02	Merck Patent GmbH	Kontinuierliche verabreichung von cilengitid in der krebstherapie
KR101737151B1 (ko) *	2009-12-04	2017-05-17	닛산 가가쿠 고교 가부시키 가이샤	2-피리돈 화합물
US8901144B2 (en)	2013-02-07	2014-12-02	Scifluor Life Sciences, Llc	Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
WO2014124302A1 (en)	2013-02-07	2014-08-14	Scifluor Life Sciences, Llc	Fluorinated integrin antagonists
GB201305668D0 (en)	2013-03-28	2013-05-15	Glaxosmithkline Ip Dev Ltd	Avs6 Integrin Antagonists
EP3050878B1 (de) *	2013-09-24	2021-10-27	FUJIFILM Corporation	Neuartige stickstoffhaltige verbindung oder salz davon oder metallkomplex davon
BR112016008276B1 (pt)	2013-10-25	2021-03-02	Novartis Ag	derivados bicíclicos de piridila fundidos ao anel, seus usos e seu intermediário, e composição farmacêutica
GB201417002D0 (en)	2014-09-26	2014-11-12	Glaxosmithkline Ip Dev Ltd	Novel compound
GB201417011D0 (en)	2014-09-26	2014-11-12	Glaxosmithkline Ip Dev Ltd	Novel compounds
GB201417018D0 (en)	2014-09-26	2014-11-12	Glaxosmithkline Ip Dev Ltd	Novel compounds
GB201417094D0 (en)	2014-09-26	2014-11-12	Glaxosmithkline Ip Dev Ltd	Novel compounds
WO2016134223A2 (en)	2015-02-19	2016-08-25	Scifluor Life Sciences, Inc.	Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
US9802917B2 (en)	2015-03-25	2017-10-31	Novartis Ag	Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
CN107428755B (zh) *	2015-03-25	2020-03-03	富士胶片株式会社	含氮化合物或其盐的制造方法以及它们的制造中间体
GB201604680D0 (en)	2016-03-21	2016-05-04	Glaxosmithkline Ip Dev Ltd	Chemical Compounds
MX2019000043A (es) *	2016-07-05	2019-07-04	Univ Rockefeller	Antagonistas de integrina de tetrahidronaftiridinpentanamida.
CN109996541A (zh)	2016-09-07	2019-07-09	普利安特治疗公司	N-酰基氨基酸化合物及其使用方法
LT3660004T (lt)	2016-10-11	2023-06-12	Arvinas Operations, Inc.	Junginiai ir metodai, skirti tikslinei androgeno receptoriaus degradacijai
EP3577109A4 (de)	2017-01-31	2020-11-18	Arvinas Operations, Inc.	Cereblonliganden und bifunktionale verbindungen damit
US11046685B2 (en)	2017-02-28	2021-06-29	Morphic Therapeutic, Inc.	Inhibitors of (α-v)(β-6) integrin
SG11201907820SA (en)	2017-02-28	2019-09-27	Morphic Therapeutic Inc	Inhibitors of (alpha-v)(beta-6) integrin
LT3761980T (lt) *	2018-03-07	2024-03-12	Pliant Therapeutics, Inc.	Aminorūgščių junginiai ir jų panaudojimo būdai
WO2019210200A1 (en) *	2018-04-27	2019-10-31	Arrowhead Pharmaceuticals, Inc.	Integrin targeting ligands and uses thereof
TWI841573B (zh) *	2018-06-27	2024-05-11	美商普萊恩醫療公司	具有未分支連接子之胺基酸化合物及使用方法
ES3027421T3 (en) *	2018-08-29	2025-06-13	Morphic Therapeutic Inc	Inhibitors of (alpha-v)(beta-6) integrin
UY38352A (es) *	2018-08-29	2020-03-31	Morphic Therapeutic Inc	Inhibidores de integrina alfavbeta6
CA3109534A1 (en)	2018-08-29	2020-03-05	Morphic Therapeutic, Inc.	Inhibiting .alpha.v .beta.6 integrin
EP3843727A4 (de)	2018-08-29	2022-08-17	Morphic Therapeutic, Inc.	Inhibitoren von (alpha-v)(beta-6)-integrin
EP3908288A4 (de)	2019-01-09	2023-12-20	Arrowhead Pharmaceuticals, Inc.	Rnai-mittel zur hemmung der expression von hif-2 typ (epas1), zusammensetzungen davon und verwendungsverfahren
US11419869B2 (en)	2019-04-08	2022-08-23	Pliant Therapeutics, Inc.	Dosage forms and regimens for amino acid compounds
EP4077309A1 (de)	2019-12-19	2022-10-26	Arvinas Operations, Inc.	Verbindungen und verfahren für gezielten abbau des androgenrezeptors
EP4146642A1 (de)	2020-05-09	2023-03-15	Arvinas Operations, Inc.	Verfahren zur herstellung einer bifunktionellen verbindung, ultrareine formen der bifunktionellen verbindung und dosierungsformen damit
CN114507202B (zh) *	2022-01-26	2023-10-03	海南大学	一种桑辛素类化合物及其制备方法与应用
GB202209228D0 (en)	2022-06-23	2022-08-10	Univ Strathclyde	Modified amino acids and uses thereof
WO2025122895A1 (en)	2023-12-08	2025-06-12	Arvinas Operations, Inc.	Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3843798A (en) *	1973-03-12	1974-10-22	Stanley Drug Products Inc	Methods and compositions for inducing resistance to bacterial infections
FR2466252A2 (fr) *	1979-10-03	1981-04-10	Clin Midy	Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine
US5025025A (en) *	1989-06-28	1991-06-18	Ciba-Geigy Corporation	(Arylsulfonamido- and pyridyl-)-substituted carboxylic acids and derivatives thereof and use for suppressing thromboxane activity
FR2658511B1 (fr) *	1990-02-16	1992-06-19	Union Pharma Scient Appl	Nouveaux derives de benzimidazole et d'azabenzimidazole, antagonistes des recepteurs au thromboxane; leurs procedes de preparation, compositions pharmaceutiques les contenant.
EP0578745A1 (de) *	1991-04-04	1994-01-19	The Upjohn Company	Phosphorhaltige verbindungen als inhibitoren von retroviren
US5352667A (en) *	1991-11-22	1994-10-04	Ofer Lider	Non-peptidic surrogates of the Arg-Gly-Asp sequence and pharmaceutical compositions comprising them
US5252591A (en) *	1992-08-14	1993-10-12	G. D. Searle & Company	Pyridinyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension
JP3322878B2 (ja) *	1992-10-14	2002-09-09	メルクエンドカンパニーインコーポレーテッド	フィブリノーゲンレセプターアンタゴニスト
CN1142832A (zh) *	1993-12-06	1997-02-12	赛特尔公司	Cs-1模拟肽，利用该肽的组合物和方法
CA2190870A1 (en) *	1994-05-27	1995-12-07	George D. Hartman	Compounds for inhibiting osteoclast-mediated bone resorption
US5650386A (en) *	1995-03-31	1997-07-22	Emisphere Technologies, Inc.	Compositions for oral delivery of active agents
ES2197950T3 (es) *	1995-06-29	2004-01-16	Smithkline Beecham Corporation	Antagonistas del receptor de la integrina.
WO1997026250A1 (en) *	1996-01-16	1997-07-24	Merck & Co., Inc.	Integrin receptor antagonists

1998
- 1998-12-14 WO PCT/US1998/026484 patent/WO1999031061A1/en not_active Ceased
- 1998-12-14 EA EA200000660A patent/EA002822B1/ru not_active IP Right Cessation
- 1998-12-14 JP JP2000538988A patent/JP3585839B2/ja not_active Expired - Fee Related
- 1998-12-14 ES ES98963136T patent/ES2241192T3/es not_active Expired - Lifetime
- 1998-12-14 PL PL98341215A patent/PL341215A1/xx unknown
- 1998-12-14 BR BR9813769-7A patent/BR9813769A/pt not_active IP Right Cessation
- 1998-12-14 TR TR2000/02557T patent/TR200002557T2/xx unknown
- 1998-12-14 CN CN98813567A patent/CN1284944A/zh active Pending
- 1998-12-14 KR KR1020007006677A patent/KR20010033248A/ko not_active Ceased
- 1998-12-14 SK SK919-2000A patent/SK9192000A3/sk unknown
- 1998-12-14 NZ NZ504893A patent/NZ504893A/xx unknown
- 1998-12-14 ID IDW20001164A patent/ID24955A/id unknown
- 1998-12-14 AT AT98963136T patent/ATE294163T1/de not_active IP Right Cessation
- 1998-12-14 GE GEAP19985463A patent/GEP20032921B/en unknown
- 1998-12-14 CA CA002315220A patent/CA2315220C/en not_active Expired - Fee Related
- 1998-12-14 EE EEP200000362A patent/EE200000362A/xx unknown
- 1998-12-14 AU AU18220/99A patent/AU739811B2/en not_active Ceased
- 1998-12-14 IL IL13649598A patent/IL136495A0/xx unknown
- 1998-12-14 HU HU0100397A patent/HUP0100397A3/hu unknown
- 1998-12-14 DE DE69829996T patent/DE69829996T2/de not_active Expired - Fee Related
- 1998-12-14 HR HR20000401A patent/HRP20000401A2/hr not_active Application Discontinuation
- 1998-12-14 EP EP98963136A patent/EP1040098B1/de not_active Expired - Lifetime
2000
- 2000-05-31 IS IS5521A patent/IS5521A/is unknown
- 2000-06-16 NO NO20003114A patent/NO20003114L/no unknown
- 2000-07-13 BG BG104605A patent/BG104605A/bg unknown

Also Published As

Publication number	Publication date
NZ504893A (en)	2002-10-25
SK9192000A3 (en)	2001-03-12
CN1284944A (zh)	2001-02-21
JP3585839B2 (ja)	2004-11-04
EP1040098A1 (de)	2000-10-04
KR20010033248A (ko)	2001-04-25
BR9813769A (pt)	2000-10-10
AU1822099A (en)	1999-07-05
DE69829996D1 (de)	2005-06-02
GEP20032921B (en)	2003-03-25
AU739811B2 (en)	2001-10-18
EP1040098A4 (de)	2002-10-30
ID24955A (id)	2000-08-31
NO20003114D0 (no)	2000-06-16
IL136495A0 (en)	2001-06-14
EA200000660A1 (ru)	2001-02-26
ES2241192T3 (es)	2005-10-16
TR200002557T2 (tr)	2000-12-21
NO20003114L (no)	2000-08-16
IS5521A (is)	2000-05-31
EP1040098B1 (de)	2005-04-27
PL341215A1 (en)	2001-03-26
WO1999031061A1 (en)	1999-06-24
HUP0100397A3 (en)	2002-10-28
HRP20000401A2 (en)	2001-12-31
EA002822B1 (ru)	2002-10-31
CA2315220C (en)	2006-03-21
EE200000362A (et)	2001-12-17
JP2002508355A (ja)	2002-03-19
DE69829996T2 (de)	2006-02-23
HUP0100397A2 (hu)	2001-09-28
CA2315220A1 (en)	1999-06-24
BG104605A (bg)	2001-05-31

Legal Events

Date	Code	Title	Description
2005-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
NO20003114D0 (no)	2000-06-16	Integrinreseptorantagonister
ATE298338T1 (de)	2005-07-15	Integrin-rezeptor-antagonisten
DE69830806D1 (de)	2005-08-11	Integrinrezeptor antagonisten
ATE236626T1 (de)	2003-04-15	Integrin antagonist
CA2277273A1 (en)	1998-07-23	Integrin antagonists
ES2185009T3 (es)	2003-04-16	Antagonistas de alfa y beta 3'.
ATE368462T1 (de)	2007-08-15	Alpha v integrin-rezeptor antagonisten
EP1315501A4 (de)	2005-03-23	Alpha v integrin-rezeptor-antagonisten
YU38200A (sh)	2003-12-31	Antagonisti integrinskog receptora
YU38300A (sh)	2002-12-10	Antagonisti integrinskog receptora
ECSP992897A (es)	1999-06-01	Antagonistas del receptor de integrina